Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Stomach Neoplasms 20Carcinoma, Non-Small-Cell Lung 18Neoplasms 10Adenocarcinoma 8Neoplasm Metastasis 7Colorectal Neoplasms 7Carcinoma, Hepatocellular 6Esophageal Neoplasms 5Carcinoma, Renal Cell 5Breast Neoplasms 5Colonic Neoplasms 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Melanoma 3Liver Neoplasms 3Biliary Tract Neoplasms 3Ureteral Neoplasms 2Solid Tumors 2Sarcoma 2Rectal Neoplasms 2Ovarian Neoplasms 2Non-small Cell Lung Cancer Metastatic 2Malignant Solid Tumor 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Transitional Cell 2Solid Tumor 1Solid Cancer 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Ramucirumab × Clear all
NCT02564198 2021-08-17

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Eli Lilly and Company

Phase 1 Completed
29 enrolled 12 charts
CNS

Neoplasms, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡